Trump administration nears deals with pharmaceutical companies to offer obesity drugs for $149 a month

The Trump administration is reportedly nearing deals with Eli Lilly and Novo Nordisk to offer popular GLP-1 obesity drugs, including Wegovy and Zepbound, for as low as $149 per month, a substantial reduction from their current list prices of $1,000-$1,350. These agreements are expected to facilitate Medicare coverage for certain beneficiaries, which would significantly expand the market for these high-demand medications. While not yet finalized, these negotiations are part of a broader White House initiative to lower drug prices through direct deals with pharmaceutical manufacturers, potentially impacting the revenue models and market penetration strategies for key players in the rapidly growing weight-loss drug sector.

Analysis

The Trump administration is reportedly nearing agreements with Eli Lilly (LLY) and Novo Nordisk (NVO) to significantly reduce the consumer price of popular GLP-1 obesity drugs, such as Wegovy, Zepbound, and Mounjaro, to as low as $149 per month from current list prices of $1,000-$1,350. These potential deals are anticipated to enable Medicare coverage for certain beneficiaries, which would substantially broaden market access for these high-demand medications. This initiative aligns with a broader White House push to lower drug prices through direct negotiations with pharmaceutical manufacturers.
For LLY and NVO, these agreements could transform market dynamics, potentially offsetting lower per-unit revenue with vastly increased volume and market penetration, especially within the Medicare segment. Novo Nordisk's CEO, Mike Doustdar, has already noted the growing "consumer market" nature of weight-loss drugs, with cash-pay options like Ozempic/Wegovy at $499/month and Zepbound at $349/month already seeing significant uptake. The "Most Favored Nation" initiative has previously involved Pfizer (PFE) and AstraZeneca (AZN) in similar direct-to-consumer pricing strategies.
Despite the "moderately positive" sentiment, the tone remains "speculative" as the deals are not finalized and key policy details are still being negotiated, as confirmed by White House officials. The exact drugs included and access restrictions are unclear, introducing an element of uncertainty regarding the full scope of market impact. Furthermore, the political context, including past debates over Medicare coverage and the ongoing Medicare drug price negotiations for Ozempic and Wegovy, underscores the complex regulatory environment.

Key Decisions for Investors

• Investors should closely monitor the finalization of these deals and the specific terms, including which drugs are covered and any access restrictions, to accurately assess the revenue implications for Eli Lilly and Novo Nordisk.
• Evaluate the potential for significant volume expansion through Medicare coverage against the impact of reduced per-unit pricing on profitability for LLY and NVO.
• Consider the broader regulatory precedent these "Most Favored Nation" deals set for pharmaceutical pricing and market access across the industry, potentially impacting other drug manufacturers.